NIOX Group PLC (NIOX)
Industry Medical Devices
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
67.20p
Buy
69.20p
1.00p (+1.48%)
Prices updated at 12 Dec 2025, 16:35 GMT
| Prices minimum 15 mins delay
Prices in GBX
Circassia Pharmaceuticals PLC is a biotechnology company. It is engaged in the development and commercialization of range of therapies for asthma and chronic obstructive pulmonary disease.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 37m | 42m | |
| 27m | 30m | |
| 5m | 8m | |
| 12.50 | 18.42 | |
| 11m | 4m | |
| 9m | 12m | |
| Sales, General and administrative | 20m | 20m |
| Interest expenses | 100,000 | 100,000 |
| Provision for income taxes | -5m | 4m |
| Operating expenses | 22m | 23m |
| Income before taxes | 4m | 8m |
| Net income available to common shareholders | 11m | 4m |
| 0.0255 | 0.0088 | |
| Net interest income | 600,000 | 700,000 |
| Advertising and promotion | - | - |
| Net investment income, net | -1m | -500,000 |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | 0.0238 | 0.0083 |
| Free cash flow per share | 0.0236 | 0.0266 |
| Book value/share | 0.1922 | 0.2055 |
| Debt equity ratio | 0.005967 | 0.013445 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 34m | 21m |
| Current liabilities | 7m | 8m |
| Total capital | 84m | 60m |
| Total debt | 1m | 2m |
| Total equity | 84m | 60m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 92m | 68m |
| Total liabilities | - | - |
| Cash and cash equivalents | 20m | 11m |
| Common stock | 421m | 398m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 19m | 20m |
| Cash dividends paid | -10m | -4m |
| 11m | 16m | |
| Investments (gains) losses | -300,000 | -1m |
| 20m | 11m | |
| Net income | - | - |
| 12m | 17m | |
| -300,000 | -1m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.